BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is pleased to announce highly promising results from a two-arm phase 1 clinical study of the safety and
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-08 8:00 AM EST | BioVaxys Technology Corp.
MyndTec Inc. Completes Additional Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - January 7, 2026) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed an additional tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The additional tranche of the private placement, the tenth of the Offering, consists of 618,118 Units of the Company (t
Technology, Healthcare and Hospitals, Health
2026-01-07 6:00 PM EST | MyndTec Inc.
Apollo Biowellness, Inc., Announces Expiration of Letter of Intent, Negotiations Continue
North Bergen, New Jersey--(Newsfile Corp. - January 7, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), announces that the Letter of Intent between the Company and Revive Regenerative, Inc., dated September 12, 2025, (the "LOI") has expired and it no longer in effect.
Household / Consumer / Cosmetics, Health
2026-01-07 9:30 AM EST | Apollo Biowellness, Inc.
Broadreach Medical Resources (BMR) Announces Rebrand to HarmonyRx, Reflecting a New Era of Clinical-First Pharmacy Benefit Management
New York, New York--(Newsfile Corp. - January 7, 2026) - Broadreach Medical Resources (BMR), a leader in pharmacy benefit consulting and strategic clinical management, announces our rebrand to HarmonyRx-a name that represents the company's evolution, mission and commitment to aligning clinical excellence with financial value. The new brand identity reflects HarmonyRx's philosophy: that the most effective pharmacy strategies bring together evidence, clinical insight and cost stewardship
2026-01-07 8:08 AM EST | HarmonyRx
Glow Lifetech Expands into Medical Cannabis Channel with National Launch on Mendo Medical
Toronto, Ontario--(Newsfile Corp. - January 7, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce the launch of its MOD™ and .decimal™ product portfolio on the Mendo Medical Cannabis platform ("Mendo"), representing Glow's first formal entry into the Canadian medical cannabis channel and extending access to its products for registered medical patients nationwide. This launch represents an important
2026-01-07 7:30 AM EST | Glow Lifetech Corp.
BioHarvest Sciences Issues Year End Shareholder Letter
British Columbia and Rehovot, Israel--(Newsfile Corp. - January 7, 2026) - BioHarvest Sciences Inc., (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today issued a letter to shareholder partners from Chief Executive Officer, Ilan Sobel. Dear Fellow Shareholders, 2025 marked an important milestone for BioHarvest Scie
Biotechnology, Pharmaceuticals, Health
2026-01-07 7:30 AM EST | BioHarvest Sciences Inc.
TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce its first commercial order in Israel and the successful delivery of an initial shipment to the warehouse of Guri A.A.O. ("Guri"), a leading Israeli medical distribution company.
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-06 5:00 PM EST | TempraMed Technologies Ltd.
PhantomOmics Announces Clinical Collaboration with Banff Sport Medicine to Advance Non-Invasive Health Scanning Protocols
Calgary, Alberta--(Newsfile Corp. - January 6, 2026) - PhantomOmics Inc., a Calgary-based health technology company developing non-invasive, AI-powered health scanning systems, today announced a new clinical collaboration with Banff Sport Medicine, one of Canada's leading orthopaedic and sport medicine clinics.
Technology, Healthcare and Hospitals, Sensor, Health
2026-01-06 4:27 PM EST | PhantomOmics Inc.
St. Baldrick's Foundation Announces 2026 Ambassadors
Los Angeles, California--(Newsfile Corp. - January 6, 2026) - The St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants in the U.S., is proud to announce its 2026 Ambassadors. Along with their families, these ambassadors will share their personal journeys and experiences with childhood cancer to raise awareness and inspire action to
2026-01-06 12:00 PM EST | St. Baldrick's Foundation
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatment of neurological disorders, today announced that it will be participating in the YAFO Capital Access Asia 2025 Partnering Forum, held in San Franc
2026-01-06 8:00 AM EST | BetterLife Pharma Inc.
Aleen Inc. Announces Upcoming Enhancements to the Personal Account
Toronto, Ontario--(Newsfile Corp. - January 6, 2026) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, announces that starting in early 2026, it will begin rolling out new features and improvements within the Personal Account, its user-facing tool for managing wellness information. Planned enhancements include improved data organization, interactive visualizations, and a refined user experience, helping users gain clearer insights into personal wellness patterns wit
2026-01-06 8:00 AM EST | Aleen Inc.
Beckett's Kicks Off Multi-Channel Dry January Campaign Across Retail, Subscription Services, and Influencer Partnerships
Ontario and Los Angeles, California--(Newsfile Corp. - January 6, 2026) - Beckett's Inc. (CSE: BKTS) (OTCQB: BKTSF), a fast-growing non-alcoholic beverage brand has launched a national Dry January initiative spanning major retail, subscription, and influencer channels. The month-long campaign includes featured promotions at Total Wine & More, Walmart.com, Amazon.com, national non-alcoholic subscription service Raising the Bar, Los Angeles bottle shop Burden of Proof, along w
Food / Beverages, Cannabis, Health
2026-01-06 7:30 AM EST | Becketts Inc.
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - January 5, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the "Notes"), the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on December 31, 2025. The Company expects to issue the Common Shares no later than Januar
2026-01-05 5:30 PM EST | Rapid Dose Therapeutics Corp.
Adia Nutrition Inc. Announces Landmark Autism Spectrum Disorder Clinical Study Now Live on ClinicalTrials.gov
Winter Park, Florida--(Newsfile Corp. - January 5, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine through its subsidiary Adia Med, today announced that its patent-pending clinical study targeting Autism Spectrum Disorder (ASD) has gone live on ClinicalTrials.gov, marking a significant advancement in the company's research pipeline.
Healthcare and Hospitals, Health
2026-01-05 10:21 AM EST | Adia Nutrition Inc.
RELIEF AI's Digital Well-Being Innovation "RELIEF AI - Naia" Recognized as a "Recommended Measure for 2025" by Leading German Health Promotion Organization
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - Relief AI Inc. (the "Company "or "Relief AI") is proud to announce that its groundbreaking digital well-being solution, RELIEF AI - Naia, has been officially recognized as a "Recommended Measure 2025" by the Gesellschaft für Prävention (GpeV), a leading German health promotion organization. This official recognition was granted after a thorough review and evaluation by the GPeV, which cited the exceptional value of
Technology, Healthcare and Hospitals, Health
2026-01-05 7:00 AM EST | Relief AI Inc.
CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition
Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Exe
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-01-05 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead in 2026. As 2025 ends, the Company reflects on a transformative year marked by significant commercial progress, strategi
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-02 5:00 PM EST | TempraMed Technologies Ltd.
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, announces that it has extended the term of a consulting agreement, as amended, previously announced June 11, 2025 and November 21, 2025, with a third party branding expert to provide strate
Technology, Healthcare and Hospitals, Health
2025-12-31 6:00 PM EST | FendX Technologies Inc.
TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce today a new commercial order and an extension of its distribution partnership in South Korea. The expanded collaboration with Mavericks Co. Ltd ("Mavens"), a South Korea–
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-31 5:00 PM EST | TempraMed Technologies Ltd.
Izotropic Announces AGM Results
British Columbia and Sacramento, California--(Newsfile Corp. - December 31, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the results of its Annual General and Special Meeting held on December 29, 2025. Company mat
2025-12-31 4:31 PM EST | Izotropic Corporation